Chinese startup uses VR simulations to predict likelihood of drug addiction

September 24, 2019
CPG More...
“Better-for-You” Transformation More...
Claims More...
Average importance

WonderLab (Wangli Technology) uses VR to simulate drug abuse scenes and studies the user's pulse, brain waves, and electrical conductance of the skin. It uses AI to analyze the data, which then generates a drug craving score. It claims an accuracy of more than 90% in predicting drug addiction. The startup is already working with rehabilitation centers in more than 10 Chinese provinces and is also in discussion with Cambodian authorities to introduce the technology there. Clients might recall a similar product from Pear Therapeutics, reSET, that aims to tackle opioid abuse. While Pear takes a treatment approach, WonderLab takes a preventative approach, predicting drug abuse before it happens, which is a more powerful approach.

For the original news article, click here .

Further Reading

Nvidia continues to forge partnerships to develop new approaches for AI-based drug discovery

News Commentary | April 19, 2021

Drug discovery is an expensive process. More than 96% of all drug development projects fail. Nvidia is one of many tech players looking to address this gap. It will use a new approach called transformer neural networks. The transformer model architecture is powerful for modeling sequences, whether ... Not part of subscription

Facebook and Helmholtz Zentrum München unveil open-source AI model to help predict drug combinations for cancer treatment

News Commentary | April 21, 2021

Computational methods for exploring new combinations have been limited to drug interactions included in the training data set and break down when handling more complex changes like different doses and timing. The Compositional Perturbation Encoder (CPA) claims a novel self‑supervision technique that... Not part of subscription

Is it time for AI for drug discovery as a service?

Case Study | October 25, 2021

Despite the value of AI to the pharmaceutical industry in the drug discovery space, significant barriers to its adoption remain. One of the major barriers lies in developing the relevant AI capabilities to tackle questions around novel target identification, lead identification and optimization, ... Not part of subscription